BWFA
VRTX icon

Baltimore-Washington Financial Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Baltimore-Washington Financial Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-46
Closed -$4K – 252
2015
Q3 		$4K Buy
+46
New +$5.91K ﹤0.01% 231

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Baltimore-Washington Financial Advisors's VRTX Position: Q4 2015 in Review

Baltimore-Washington Financial Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q4 2015, closing a stake of 46 shares — an estimated $4K sold.

Baltimore-Washington Financial Advisors first reported a position in VRTX in Q3 2015 and held it in 1 quarter. The position peaked at $4K in Q3 2015. 517 funds tracked by Wall St. Rank hold VRTX as of Q4 2015.

  • Baltimore-Washington Financial Advisors reported no remaining Vertex Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Baltimore-Washington Financial Advisors sold 46 Vertex Pharmaceuticals shares in Q4 2015, an estimated $4K.
  • Baltimore-Washington Financial Advisors first reported a position in Vertex Pharmaceuticals in Q3 2015 and held it in 1 quarter.
  • Baltimore-Washington Financial Advisors's Vertex Pharmaceuticals position peaked at $4K in Q3 2015.
  • 517 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2015.

Based on Baltimore-Washington Financial Advisors's 13F filing for Q4 2015, filed 1 Feb 2016.